mRNA 癌症疫苗的全球市場：臨床試驗與未來展望（2024 年）

Global mRNA Cancer Vaccines Clinical Trials & Market Future Outlook 2024

出版日期: 2024年06月01日 | 出版商:

KuicK Research | 英文 160 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

自從使用 mRNA 疫苗來治療冠狀病毒的那些令人興奮的日子以來，2019 年臨床研究人員正在努力利用 mRNA 疫苗來治療癌症疾病。基於mRNA疫苗治療冠狀病毒的勝利，許多研究人員認為尖端的mRNA疫苗由於其獨特的作用機制可以用於治療癌症患者。因此，mRNA癌症疫苗市場預計在未來幾年將進一步擴大。目前該領域的研發市場存在於美國和中國，但其他地區如歐洲國家也是新興地區，臨床前和臨床試驗證明了這一點。

迄今為止，還沒有mRNA 癌症疫苗進入商業化的全球市場，兩種mRNA 候選疫苗CMB-305 和mRNA 4157 的結合物正處於後期開發（III 期），鑑於目前的情況，預計會出現突破性的mRNA癌症疫苗。

迄今為止，在這種創新療法的變革潛力以及研發方面的重大進展的推動下，全球 mRNA 癌症疫苗領域經歷了前衛的成長。越來越多的研究表明，mRNA 癌症疫苗具有治療癌症的潛力，並且表現出更安全、更好的耐受性，從而開闢了新的途徑。雖然mRNA癌症疫苗主要用於治療實體腫瘤，但在不久的將來mRNA疫苗也將用於治療血癌。

儘管全球市場上mRNA癌症疫苗的開發進展順利，但它面臨許多課題和致命弱點，包括長期療效和其他治療方法的競爭。另一方面，臨床試驗管線強勁，未來mRNA癌症疫苗領域有望迎來狂熱的發展，為製藥公司推進mRNA癌症疫苗領域提供了機會。

本報告檢視了全球 mRNA 癌症疫苗市場，並提供了市場概況，包括藥物趨勢、臨床試驗趨勢、區域趨勢以及進入市場的公司的競爭格局。

mRNA Cancer Vaccines In Clinical Trials: > 60 Vaccines
Highest Phase Of Clinical Trials: Phase III ( 2 Vaccine)
mRNA Cancer Vaccine Clinical Trials Insight By Company, Country, Indication & Phase
First Commercial mRNA Vaccine Approval Expected By 2029
US & China Dominating mRNA Cancer Vaccines Clinical Trials: > 45 Vaccines
mRNA Vaccines For Skin Cancer Dominating Trials: > 10 Vaccines

From that time impetuous when mRNA vaccines were utilized for the management of coronavirus, in 2019, clinical researchers are working insistently with the intention of using mRNA vaccines for the treatment of cancer ailments. Building on the triumph of mRNA vaccine to cure coronavirus, copious researchers believed that cutting edge mRNA vaccines can be used to treat cancer patients owing to its exclusive mode of action. For that reason, it can be forecast that the market for mRNA cancer vaccine is expected to advance further in the imminent years. Currently, the market for this segment exists in the US coupled with China in terms of research and development; however, other regions, like European countries, are also an emerging area as evident from preclinical and clinical studies.

Until now, no mRNA cancer vaccines have entered into the commercial global market, with 2 mRNA vaccines contenders, CMB-305 in conjugation with mRNA 4157, being in the late phase of development (phase III), it can be prophesied that first breakthrough mRNA cancer vaccine will enter into the global market in upcoming 5-7 years and we contemplates that the casement of first mRNA cancer vaccine will result in an overall revenue of US$ 100 Million after its approval within 12-18 months. According to KuicK Research recent study on global mRNA clinical landscape, 3 to 4 mRNA cancer vaccines are likely to commercially enter the market in following decennium. As well as, with cumulative sales clenches plausibility of more than US$ 5 Billion in years to come.

For that reason, several mRNA cancer vaccines preclinical and clinical trials are ongoing in the domain. For instance, The V Foundation for Cancer Research in collaboration with University of Florida are planning to initiate a phase I/II clinical trial in order to examine the safety as well as immunologic activity of RNA lipid Particle (RNA-LP) Vaccines in patients with recurrent pulmonary osteosarcoma. It is an interventional study, which has an estimated study start date in August 2024 and is projected to be complete by October 2026.

Above this, the domain of mRNA cancer vaccine is experiencing trailblazing growth due to increasing research collaboration, and investments. For instance, in June 2024, Moderna has joined hands with Merck by announcing 3 year data for mRNA-4157 (V940) in combination with Keytruda (pembrolizumab) which established sustained improvement in patients suffering from high-risk stage III/IV melanoma following complete resection. Moreover, the University of Texas MD Anderson Cancer Center in addition to CureVac N.V. proclaimed a co-development along with licensing agreement in order develops novel mRNA-based cancer vaccines in April 2024.

Coupled with collaborations, advancement in technological and drug delivery is also another aspect which is influencing global mRNA cancer vaccine growth. For instance, in August 2023, healthcare professionals from Johns Hopkins Medicine have developed a nanoparticle based design which clenches plausibility to enhance mRNA cancer vaccine delivery.

Hitherto, the global sector of mRNA cancer vaccine has acknowledged an avant-garde growth, fueled by the noteworthy progression in research and development, in addition to the transformative potential of this innovative treatment modality. Accumulating studies have revealed that mRNA cancer vaccines clenches potential of treating cancer and exemplifies safer as well as well tolerated profile, thereby, offering novel avenue. Albeit, mRNA cancer vaccines are predominately used to treat solid tumors; nonetheless, treatment of hematological cancer malignancies by mRNA vaccines are likewise to be utilized in imminent years.

There is a favorable prospect in addition to development mRNA cancer vaccine in the global market but with a number of hardships and Achilles heels, like long term effectiveness and competition from other therapies. In the meantime, there exists a robust and cumbersome pipeline of clinical trials; hence, it is expected that the realm of mRNA cancer vaccine clenches enthusiastic forthcoming; representing an opportunity for pharma companies to advance the realm of mRNA cancer vaccine.

1. mRNA Vaccines as Next Generation Cancer Immunotherapy

1.1 mRNA Vaccines Overview
1.2 mRNA Vaccines v/s Other Cancer Therapeutic Approaches
1.3 mRNA Vaccines v/s Other Vaccines

2. Global mRNA Cancer Vaccine Clinical Trials Insight By Company, Country, Indication & Phase

2.1 Research
2.2 Preclinical
2.3 Phase I
2.4 Phase I/II
2.5 Phase II
2.6 Phase II/III
2.7 Phase III

3. Global Cancer mRNA Vaccines Clinical Pipeline Overview

3.1 By Company
3.2 By Country
3.3 By Indication
3.4 By Patient Segment
3.5 By Phase
3.6 By Priority Status

4. Global mRNA Cancer Vaccines Market Overview

4.1 Current Market Trends
4.2 Future Market Commercialization & Clinical Opportunities

5. Global mRNA Cancer Vaccines Market Trends by Country

5.1 US
5.2 China
5.3 Australia
5.4 Europe
5.5 Canada
5.6 UK

6. Global mRNA Cancer Vaccines Clinical Landscape by Indication

6.1 Breast Cancer
6.2 Brain Cancer
6.3 Melanoma
6.4 Colorectal Cancer
6.5 Head & Neck Cancers
6.6 Lung Cancer
6.7 Cervical Cancer
6.8 Digestive System Cancer

7. Global mRNA Cancer Vaccines Market Collaborations, Deals & Investments

8. Proprietary Technologies & Methodologies for mRNA Cancer Vaccine Development

8.1 FixVac - BioNTech
8.2 iNeST - BioNTech
8.3 NanoReady - Samyang Holdings
8.4 CureVac Method - CureVac
8.5 mRNA platform - Moderna
8.6 NeoCura Ag - NeoCura
8.7 OligoPhore(TM) and SemaPhore(TM) - Altamira Therapeutics
8.8 mRNA Medicines Platform & Proprietary LNP Delivery Technology - Providence

Therapeutic

8.9 RNAimmune

9. Competitive Landscape

9.1 BioNTech
9.2 Combined Therapeutics
9.3 CureVac
9.4 EpiVax
9.5 HDT Bio
9.6 Immorna
9.7 Immune Design
9.8 MDimune
9.9 Moderna Therapeutics
9.10 NeoCura
9.11 pHion Therapeutics
9.12 Providence Therapeutics
9.13 Regen BioPharma
9.14 RNAimmune
9.15 TransCode Therapeutics

簡介目錄圖表

List of Figures

Figure 3-1: Global - mRNA Cancer Vaccines Clinical Pipeline by Company (Numbers), 2024
Figure 3-2: Global - mRNA Cancer Vaccines Clinical Pipeline by Country (Numbers), 2024
Figure 3-3: Global - mRNA Cancer Vaccines Clinical Pipeline by Indication (Numbers), 2024
Figure 3-4: Global - mRNA Cancer Vaccines Clinical Pipeline by Patient Segment (Numbers), 2024
Figure 3-5: Global - mRNA Cancer Vaccines Clinical Pipeline by Phase (Numbers), 2024
Figure 3-6: Global - mRNA Cancer Vaccines Clinical Pipeline by Priority Status (Numbers), 2023
Figure 6-1: KEYNOTE-603 Phase I (NCT03313778) Study - Initiation & Completion Year
Figure 6-2: Autogene Cevumeran Phase I (NCT03289962) Study - Initiation & Completion Year
Figure 6-3: CVGBM Phase I (NCT05938387) Study - Initiation & Completion Year
Figure 6-4: Autogene Cevumeran Phase I (NCT03289962) Study - Initiation & Completion Year
Figure 6-5: BNT111 Phase I (NCT04526899) Study - Initiation & Completion Year
Figure 6-6: mRNA-4157 Phase II (NCT03897881) Study - Initiation & Completion Year
Figure 6-7: mRNA-4157 Phase III (NCT05933577) Study - Initiation & Completion Year
Figure 6-8: BNT122 Phase II (NCT04486378) Study - Initiation & Completion Year
Figure 6-9: BNT113 Phase II (NCT04534205) Study - Initiation & Completion Year
Figure 6-10: mRNA-4157 Phase I (NCT03313778) Study - Initiation & Completion Year
Figure 6-11: BI1361849 Phase I/II (NCT03164772) Study - Initiation & Completion Year
Figure 6-12: V940 Phase III (NCT06077760) Study - Initiation & Completion Year
Figure 6-13: Autogene cevumeran Phase I (NCT04161755) Study - Initiation & Completion Year
Figure 6-14: Autogene cevumeran Phase II (NCT05968326) Study - Initiation & Completion Year
Figure 8-1: BioNTech - uRNA products
Figure 8-2: BioNTech - iNeST technology
Figure 8-3: CureVac - CureVac Method for Generation of mRNA Therapeutics
Figure 8-4: Moderna - mRNA Technology
Figure 8-5: NeoCura - NeoCura Ag Platform
Figure 8-6: Providence Therapeutic - mRNA Medicines Platform Benefits

List of Tables

Table 1-1: mRNA Vaccines v/s Other Cancer Therapeutic Approaches
Table 1-2: mRNA-Based Cancer Vaccines vs. Other Cancer Vaccines
Table 4-1: Regulatory Designations Granted to Investigational mRNA Cancer Vaccines
Table 5-1: Europe - Ongoing Clinical Trials for mRNA Cancer Vaccines
Table 5-2: UK - Ongoing Clinical Trials for mRNA Cancer Vaccines
Table 6-1: Breast Cancer - Some mRNA Vaccines in Clinical Trials
Table 6-2: Brain Cancer - Some mRNA Vaccines in Clinical Trials
Table 6-3: Melanoma - Some mRNA Vaccines in Clinical Trials
Table 6-4: Colorectal Cancer - Some mRNA Vaccines in Clinical Trials
Table 6-5: Head & Neck Cancer mRNA Vaccines in Clinical Trials
Table 6-6: Lung Cancer - Some mRNA Vaccines in Clinical Trials
Table 6-7: Cervical Cancer - Some mRNA Vaccines in Clinical Trials
Table 6-8: Digestive System Cancers - Some mRNA Vaccines in Clinical Trials